Harrow FY2026 EPS Forecast Decreased by Cantor Fitzgerald

Harrow, Inc. (NASDAQ:HROW) – Analysts at Cantor Fitzgerald decreased their FY2026 earnings per share estimates for shares of Harrow in a research report issued on Thursday, November 13th. Cantor Fitzgerald analyst S. Seedhouse now expects that the company will earn $0.46 per share for the year, down from their previous forecast of $2.39. Cantor Fitzgerald has a “Overweight” rating and a $94.00 price objective on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.11. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The business had revenue of $71.64 million during the quarter, compared to analysts’ expectations of $73.70 million.

A number of other equities research analysts also recently commented on HROW. HC Wainwright increased their price objective on shares of Harrow from $64.00 to $69.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Lake Street Capital boosted their target price on shares of Harrow from $42.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Craig Hallum raised their price target on Harrow from $54.00 to $64.00 and gave the company a “buy” rating in a research note on Tuesday, September 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a report on Wednesday, October 8th. Finally, B. Riley reaffirmed a “buy” rating and set a $74.00 price objective (up from $70.00) on shares of Harrow in a research report on Wednesday, October 1st. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $71.43.

Harrow Stock Down 1.4%

Shares of NASDAQ:HROW opened at $39.73 on Monday. Harrow has a fifty-two week low of $20.85 and a fifty-two week high of $50.72. The firm’s 50 day moving average price is $40.82 and its 200 day moving average price is $35.35. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -158.92 and a beta of 0.19.

Institutional Trading of Harrow

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Voya Investment Management LLC lifted its holdings in Harrow by 4,035.5% in the first quarter. Voya Investment Management LLC now owns 381,461 shares of the company’s stock valued at $10,147,000 after acquiring an additional 372,237 shares during the period. Luxor Capital Group LP acquired a new position in shares of Harrow during the 3rd quarter worth $14,807,000. New York State Common Retirement Fund increased its holdings in shares of Harrow by 1,944.7% in the 3rd quarter. New York State Common Retirement Fund now owns 213,789 shares of the company’s stock valued at $10,300,000 after purchasing an additional 203,333 shares in the last quarter. Diametric Capital LP purchased a new position in shares of Harrow in the 2nd quarter valued at about $4,748,000. Finally, Bank of America Corp DE lifted its stake in shares of Harrow by 266.8% in the second quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock valued at $6,519,000 after purchasing an additional 155,258 shares during the period. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.